Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $67
JMP Securities Maintains Incyte(INCY.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cochlear Limited (OtherCHEOF)
Incyte's Niktimvo Faces Market Challenges Despite FDA Approval: Analyst Upholds Hold Rating
Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Incyte (INCY) and Gilead Sciences (GILD)
BMO Capital Maintains Incyte(INCY.US) With Sell Rating, Maintains Target Price $48
RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $67
Wells Fargo Adjusts Price Target on Incyte to $63 From $61, Maintains Equalweight Rating
Incyte (INCY) Gets a Hold From Wells Fargo
Incyte Corporation: Revised Earnings and Cautious Hold Rating Amid Unforeseen Financial Commitment
Stifel Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $73
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)
Incyte Price Target Raised to $60.00/Share From $55.00 by Deutsche Bank
Incyte Analyst Ratings
Deutsche Bank Adjusts Incyte Price Target to $60 From $55, Maintains Hold Rating
No Data